Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Globalstar jumps 17% on report of sale process:
[url][/url][tag]https://seekingalpha.com/news/3267000-globalstar-jumps-17-percent-report-sale-process[/tag]
Bloomberg reported that the company is exploring a sale.
Cant post the link, but got a news notification (Fly on the Wall): Globalstar (GSAT) option volume is 4X daily average as shares spike. The stock up 39c to $2.30 on increasing volume of 6.8M shares after Bloomberg reported that the company is exploring a sale. In option action, 3.7K Jun 2 calls have changed hands. May 2, Jun 2,5, and Jul 2 calls are next most active. Total volume is 9.2K calls and 400 puts. 30-day implied volatility up just 1% but elevated at 102.
FNCX soaring on no news, up 40%
FNCX - Spike in volume and price, not sure why.
Nice spike in volume and price. News to follow???
NEWS: EXOlifestyle Inc. Fast Casual Brand Pizza Fusion Set to Open at Old Dominion University
MARKET WIRE 9:46 AM ET 4/6/2017
Symbol Last Price Change
EXOL 0.007up +0.0022 (+45.83%)
ARMK 36.37up -0.04 (-0.11%)
QUOTES AS OF 09:48:46 AM ET 04/06/2017
BOCA RATON, FL -- (Marketwired) -- 04/06/17 -- EXOlifestyle Inc.(EXOL) , a management firm which develops and operates innovative and healthy brands within the health & wellness industry, announced today that the Company's subsidiary, Pizza Fusion, the innovative fast casual pizza concept, announced it will be opening its newest franchised restaurant in Norfolk, Virginia in Old Dominion University's "University Village". This new restaurant marks the brand's first location with Aramark Food and Support Services Group, Inc. ("Aramark").
This location marks the first Pizza Fusion to open under a National Test License Agreement that the two companies entered on November 6th, 2015. http://www.exolifestyle.co/pr-11-06-2015
"This is an exciting, full relaunch of the Pizza Fusion brand," said CEO Vaughan Dugan. "We've worked tirelessly over the past several years on fine-tuning this concept with the goal of providing guests an elevated experience and the same fun, energetic atmosphere we are known for, while doing an even better job at providing a simplistic presentation of 'healthy' options for this industry. We are excited to bring our fresh and organic pizza concept and share it with the students and community at Old Dominion University."
The site, a former Starbucks location, is currently under development and is slated to open in time for the incoming Fall semester. The location was designed by renowned Miami design firm, Saladino Design Studio and will highlight several refreshed design elements.
Thanks, hoping the trend continues!
+15% Haven't seen it up here for a while. Wondering why...
Good week, looking forward to the next.
Definitely had some big swings this morning, I think it's due to keep moving up. Should be a nice return. GL
And volume picking up! Hopefully it'll keep the momentum. NSPR
Looks promising this morning. ATLS
Appreciate the update Doc! Hoping this'll continue the move up to where it belongs soon.
I'd agree, will be interesting to see if the market will embrace the timeline or not. So far, so good!
Innocoll announces regulatory path forward after receiving formal FDA Type A meeting minutes regarding its XARACOLL® (bupivacaine HCl collagen-matrix implant) New Drug Application
GLOBENEWSWIRE 9:15 AM ET 3/29/2017
Symbol Last Price Change
INNL 1.08 0 (0%)
QUOTES AS OF 04:00:00 PM ET 03/28/2017
ATHLONE, Ireland, March 29, 2017 (GLOBE NEWSWIRE) -- Innocoll Holdings plc(INNL) ("Innocoll" or the "Company"), a global, commercial-stage, specialty pharmaceutical and medical device company, today announced receipt of formal Type A Meeting minutes from the United States Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for XARACOLL (bupivacaine HCl collagen-matrix implant). XARACOLL is the company’s product in development for the treatment of postsurgical pain.
Innocoll (INNL) received a Refusal to File (RTF) Letter from the FDA in December 2016 pertaining to the XARACOLL NDA initially submitted on October 31, 2016. In the RTF letter, the FDA indicated among other things, that XARACOLL should be characterized as a drug/device combination, which would require that the Company submit additional information. During the Type A meeting, representatives of the FDA, after reviewing information provided by Innocoll(INNL) to address matters raised in the RTF letter, provided guidance which was confirmed in the formal FDA meeting minutes. The minutes serve as the official record of the FDA response to our proposal to address certain issues raised in the RTF by conducting an additional short-term pharmacokinetic study and several short-term non-clinical toxicology and biocompatibility studies. Innocoll(INNL) believes, if adequately financed and successful, such studies may be completed in time for a resubmission of the NDA at the end of 2017. Data from these studies, along with additional manufacturing information required to address the new combination product designation and other chemistry, manufacturing and control (CMC) issues, are expected to be included in the resubmission. The acceptability of this data and other data that we reviewed with FDA during the meeting will be evaluated by the FDA during its review of the resubmission.
“I am pleased that we have clarified the data needed to address the questions raised in the RTF letter. With the official minutes from the FDA now in hand, we believe that we have a path forward for a possible resubmission of the XARACOLL NDA by the end of 2017, assuming adequate financing to commence the proposed studies, and further assuming positive results,” said Tony Zook, CEO of Innocoll(INNL).
About XARACOLL®
XARACOLL is Innocoll’s late-stage surgically implantable and bioresorbable collagen matrix developed to provide sustained postsurgical pain relief through controlled delivery of bupivacaine at the surgical site.
About Innocoll Holdings plc(INNL)
Innocoll (INNL) is a global, commercial stage specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need. Innocoll(INNL) utilizes its proprietary collagen-based technology platform to develop biodegradable and fully bioresorbable products and product candidates which can be broken down by the body without the need for surgical removal or topical application.
Responsibility Statement
The Directors of the Company accept responsibility for the information contained in this announcement. To the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they take responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.
Forward-looking Statements
Any statements in this press release about our ongoing development of XARACOLL and our other product candidates; our interpretation of the data and results from our MATRIX-1 and MATRIX-2 clinical trials; receiving positive data from additional studies required to submit a revised NDA, our plans for, and the expected timing of, our XARACOLL NDA submission with the FDA; our plans to develop and commercialize XARACOLL and its market potential; the potential therapeutic and other benefits of XARACOLL and our other product candidates; Innocoll's(INNL) current expectations regarding future events, including statements regarding the therapeutic benefit, safety profile and commercial value of XARACOLL, plans and objectives for present and future clinical trials and results of such trials, the risk that the FDA may not accept pooled data, plans and objectives for regulatory approval and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "goal," "may", "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties including, but not limited to, the risk that the FDA and foreign regulatory authorities may not agree with our interpretation of the data from our clinical trials of XARACOLL and may require us to conduct additional clinical trials; such additional trials may not result in positive data; XARACOLL may not receive regulatory approval or be successfully commercialized, including as a result of the FDA's or other regulatory authorities' decisions regarding limitations on claims that may be made on XARACILL's label and other matters that could affect its availability or commercial potential; our plans to develop and manufacture XARACOLL;; the size and growth of the potential markets for XARACOLL and our ability to serve those markets; our manufacturing and marketing capabilities; or other actions and factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with the Securities and Exchange Commission. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. In addition, the forward-looking statements included in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In management's opinion, and as previously disclosed, Innocoll's(INNL) anticipated expenditures during the next 12 months to advance its current operations, including plans to conduct further studies to enable it to submit a revised NDA for XARACOLL and to develop COLLAGUARD will be greater than the amount of its current cash and cash equivalents. As a result, Innocoll(INNL) management has been investigating and continues to investigate strategic options for the Company to maximize shareholder value.
The scientific information discussed in this news release related to Innocoll's(INNL) product candidates is preliminary and investigative. Such product candidates are not approved by the FDA, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.
Rule 8 - Dealing Disclosure Requirements
Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Innocoll(INNL), all "dealings" in any "relevant securities" of Innocoll(INNL) (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date of the relevant transaction. This requirement will continue until the date on which the “offer period” ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an "interest" in "relevant securities" of Innocoll(INNL), they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.
A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.
"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel's website.
If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 (0)1 678 9020; fax number +353 (0)1 678 9289.
Corporate:
Pepe Carmona
Chief Financial Officer
(215) 983-3362
pcarmona@innocoll.comImage: Primary Logo
Source: Innocoll Holdings plc(INNL)
In all fairness, I agree with you, however there was a posting by this rag to expect earnings on 3/27:
https://www.thecerbatgem.com/2017/03/24/inspiremd-inc-nspr-set-to-announce-quarterly-earnings-on-monday.html
Looking good here in pre-market. Might be an interesting day.
Funny how people that say this is a scam and going to .0001 are still supposedly holding their shares. Why?
I agree, here's a link I posted a while back. Look at the dates and correlate to the price drops:
http://otcshortreport.com/?index=PMEA&action=view
I'd agree that it looks like shorts have driven it down versus any other news. They just payed off a 1.2 million dollar loan, heck that's about equal to the market cap. It should be moving up soon, unless I'm missing something (which wouldn't be the first time).
That's all I've found as well. It took a nosedive after announcements of warrants priced at 1.60 for 4+ million shares if I recall the number correctly.
This looks like it's ready to move back up.
I'd say the chances are good based on yesterday afternoon and AH. Due to run sometime soon, might as well start today :)
Agreed, $GSAT looking great!
That would be nice! I'm also curious to see whether or not any of the large block trades show up around closing or AH. Either way, when news does hit, I believe we'll start making significant gains.
Agreed! Nice volume and steadily moving up in price. $GSAT
Yep, I'm convinced of that now, good days ahead!
The timing of the notes and the wording in the 8k sure makes sense, particularly with the volume upswing at closing and the large AH purchases today. Thanks for pointing that out!
Nice start for the weekend! We may finally get our payoff for this investment! :)
Am I hallucinating? Another buy AH of 4.4 million!!!
GSAT - Volume spike in last 15 minutes of trading. 5.8 million buy at $1.47 at 16:05 in after hours.
Definitely a serious investment, good things to come!
Anyone else see the 5.8 million buy at 16:05??? $GSAT
Agreed! Looks like 5.5 million shares in the last 15 minutes. Hopefully just an early start for next week.
Volume and price increase, news pending?
LOL....Loved that!
PM&E, Inc. Has Been Approached and Offered 12,000,000 USD For The Purchase of Evada Aircraft
MARKET WIRE 1:27 PM ET 3/17/2017
Symbol Last Price Change
PMEA 0.0005up -0.0001 (-16.67%)
QUOTES AS OF 01:00:09 PM ET 03/17/2017
CHEYENNE, WY -- (Marketwired) -- 03/17/17 -- Aircraft manufacturer PM&E, Inc.(PMEA) announced today that it has been approached and offered 12,000,000 USD for the purchase of Evada Aircraft.
CEO Joseph Bourne stated, "An existing publicly traded company has divested itself of most of its business dealings, debts and assets and is looking to pursue a new business model. They like what they see with EVADA Aircraft. We want our shareholders to know that we are taking this offer very seriously. Our existing management, development and assembly team will remain intact. In addition, there are a multitude of reasons why this would also be a huge win for all existing shareholders and I will outline all of those reasons and share more details on this development in the coming few weeks. As always, we appreciate your support of our company."
http://www.pme-holding.com
Facebook : https://www.facebook.com/PME-Inc-432293210274534/
Google + : https://plus.google.com/u/0/110058910223174354829?hl=fr
Twitter : https://twitter.com/PMEA_Inc
YouTube : https://www.youtube.com/channel/UCUUREk7BtuTwfWVQEgBDqnA
LinkedIn : https://www.linkedin.com/company/10877337
Safe Harbor
Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from the results predicted and reported results should not be considered an indication of future performance. In addition to the factors discussed in the filings with the Securities and Exchange Commission, among the other factors that could cause actual results to differ materially are the following: adverse changes in the business conditions and the general economy; competitive factors, such as rival companies' pricing and marketing efforts; availability of third-party material products at reasonable prices; the financial condition of the customer; risks of obsolescence due to shifts in market demand; and litigation involving product liabilities and consumer issues. PM&E Inc.(PMEA) cautions readers not to place undue reliance upon any such forward looking statements, which speak only as of the date made. PM&E Inc.(PMEA) expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the company's expectations or any change in events, conditions or circumstances on which any such statement is based.
Mr. Joseph Bourne
President / CEO
001 (307) 392-4771
contact@pme-holding.com
Source: PM&E, Inc.(PMEA)
We'll see... I bought in too early at 1.07. Been averaging down since then. Looks like warrants issues drove price down, but from what I can tell the exercise price is 1.60. Hoping for a decent move up here short term. Thanks
PULM - Up 46% this morning, not sure why...
PULM - Up 46% this morning, not sure why...